Literature DB >> 21424305

Neoadjuvant radiochemotherapy and surgery for advanced rectal cancer : prognostic significance of tumor regression.

Hans Theodor Eich1, Anna Stepien, Christian Zimmermann, Martin Hellmich, Ralf Metzger, Arnulf Hölscher, Rolf-Peter Müller.   

Abstract

PURPOSE: Preoperative radiochemotherapy is widely used in the treatment of locally advanced rectal cancer. The predictive value of response to neoadjuvant treatment remains uncertain. We retrospectively evaluated the impact of downstaging and tumor regression as prognostic factors and its influence on the ability to perform sphincter-sparing surgery. PATIENTS AND METHODS: A total of 72 consecutive patients with advanced rectal cancer were included in this retrospective analysis. All patients were treated with preoperative 5-fluorouracil-based chemotherapy and pelvic radiation with a total dose of 50.4 Gy followed by surgery 6 weeks later.
RESULTS: A sphincter-preserving procedure could be performed on 42 patients, and in all 72 patients complete resection (R0) was achieved. A pathological complete response (ypT0, ypN0) was achieved in 8 (11%) patients. None of the patients showing a complete pathological response relapsed or died during the follow-up period. At a median follow-up of 28 months, 65 patients were alive, none of these patients had local recurrence and 15 patients had metastatic disease. Patients showing a complete pathological response had a significantly better 2-year disease-free survival compared to patients with ≥10% residual tumor cells (p = 0.024). Patients < 65 years showed a significantly better response rate, compared with those > 65 years of age (p = 0.036). Acute toxicity was moderate.
CONCLUSION: Preoperative radiochemotherapy is an effective and safe treatment for patients with locally advanced rectal cancer. Pathological parameters after preoperative radiochemotherapy, including tumor regression grading, could be correlated with disease-free survival. The impact of tumor regression grading needs to be further validated in prospective clinical trials.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21424305     DOI: 10.1007/s00066-011-2113-1

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  29 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

2.  Chemotherapy with preoperative radiotherapy in rectal cancer.

Authors:  Jean-François Bosset; Laurence Collette; Gilles Calais; Laurent Mineur; Philippe Maingon; Ljiljana Radosevic-Jelic; Alain Daban; Etienne Bardet; Alexander Beny; Jean-Claude Ollier
Journal:  N Engl J Med       Date:  2006-09-14       Impact factor: 91.245

3.  Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients.

Authors:  Carlo Capirci; Vincenzo Valentini; Luca Cionini; Antonino De Paoli; Claus Rodel; Robert Glynne-Jones; Claudio Coco; Mario Romano; Giovanna Mantello; Silvia Palazzi; Falchetti Osti Mattia; Maria Luisa Friso; Domenico Genovesi; Cristiana Vidali; Maria Antonietta Gambacorta; Alberto Buffoli; Marco Lupattelli; Maria Silvia Favretto; Giuseppe La Torre
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-11       Impact factor: 7.038

4.  Improved survival with preoperative radiotherapy in resectable rectal cancer.

Authors:  B Cedermark; M Dahlberg; B Glimelius; L Påhlman; L E Rutqvist; N Wilking
Journal:  N Engl J Med       Date:  1997-04-03       Impact factor: 91.245

5.  Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience.

Authors:  N A Janjan; V S Khoo; J Abbruzzese; R Pazdur; R Dubrow; K R Cleary; P K Allen; P M Lynch; G Glober; R Wolff; T A Rich; J Skibber
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-07-15       Impact factor: 7.038

6.  Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.

Authors:  Claus Rödel; Peter Martus; Thomas Papadoupolos; Laszlo Füzesi; Martin Klimpfinger; Rainer Fietkau; Torsten Liersch; Werner Hohenberger; Rudolf Raab; Rolf Sauer; Christian Wittekind
Journal:  J Clin Oncol       Date:  2005-10-24       Impact factor: 44.544

7.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

Authors:  Jean-Pierre Gérard; Thierry Conroy; Franck Bonnetain; Olivier Bouché; Olivier Chapet; Marie-Thérèse Closon-Dejardin; Michel Untereiner; Bernard Leduc; Eric Francois; Jean Maurel; Jean-François Seitz; Bruno Buecher; Rémy Mackiewicz; Michel Ducreux; Laurent Bedenne
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

8.  Radiochemotherapy in combination with regional hyperthermia in preirradiated patients with recurrent rectal cancer.

Authors:  Valeria Milani; Montserrat Pazos; Rolf Dieter Issels; Veit Buecklein; Sultan Rahman; Katharina Tschoep; Pamela Schaffer; Ralf Wilkowski; Eckhart Duehmke; Moshe Schaffer
Journal:  Strahlenther Onkol       Date:  2008-03       Impact factor: 3.621

Review 9.  [The role of magnetic resonance imaging to select patients for preoperative treatment in rectal cancer].

Authors:  Claus Rödel; Rolf Sauer; Rainer Fietkau
Journal:  Strahlenther Onkol       Date:  2009-08-04       Impact factor: 3.621

10.  Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial.

Authors:  Juergen Dunst; Juergen Debus; Volker Rudat; Joern Wulf; Wilfried Budach; Tobias Hoelscher; Thomas Reese; Stephan Mose; Claus Roedel; Helmut Zuehlke; Axel Hinke
Journal:  Strahlenther Onkol       Date:  2008-09-19       Impact factor: 3.621

View more
  16 in total

1.  Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advanced rectal cancer. Treatment outcome outside clinical trials.

Authors:  J Winkler; L Zipp; J Knoblich; F Zimmermann
Journal:  Strahlenther Onkol       Date:  2012-03-10       Impact factor: 3.621

2.  Oxaliplatin and capecitabine concomitant with neoadjuvant radiotherapy and extended to the resting period in high risk locally advanced rectal cancer.

Authors:  Y-H Gao; X Zhang; X An; M-Y Cai; Z-F Zeng; G Chen; L-H Kong; J-Z Lin; D-S Wan; Z-Z Pan; P-R Ding
Journal:  Strahlenther Onkol       Date:  2014-01-11       Impact factor: 3.621

3.  Genomic predictor of complete response after chemoradiotherapy in rectal cancer.

Authors:  Gyoung Tae Noh; Nam Kyu Kim
Journal:  Ann Transl Med       Date:  2016-12

4.  Tumor SUVmax Normalized to Liver Uptake on (18)F-FDG PET/CT Predicts the Pathologic Complete Response After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.

Authors:  Jihyun Park; Kyoung Jin Chang; Young Seok Seo; Byung Hyun Byun; Joon Ho Choi; Hansol Moon; Ilhan Lim; Byung Il Kim; Chang Woon Choi; Sang Moo Lim
Journal:  Nucl Med Mol Imaging       Date:  2014-08-01

5.  Time management in radiation oncology: development and evaluation of a modular system based on the example of rectal cancer treatment. The DEGRO-QUIRO trial.

Authors:  R Fietkau; W Budach; N Zamboglou; H-J Thiel; H Sack; W Popp
Journal:  Strahlenther Onkol       Date:  2011-12-24       Impact factor: 3.621

6.  Clinical outcome of rectal cancer in patients ≥ 80 years treated in southern France (PACA region) between 2002 and 2005.

Authors:  O Guerin; J Gal; E Francois; B Jacqueme; V Sciortino; J P Gerard
Journal:  Strahlenther Onkol       Date:  2012-03-14       Impact factor: 3.621

7.  Kinetically guided neoadjuvant chemoradiotherapy based on 5-Fluorouracil in patients with locally advanced rectal cancer.

Authors:  Jiří Grim; Miloš Hroch; Hroch Miloš; Jaroslav Chládek; Chládek Jaroslav; Jiří Petera; Petera Jiří; Jiřina Martínková; Martínková Jiřina
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

8.  Intraoperative radiotherapy and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Five consecutive case reports of locally advanced rectal cancer with synchronous peritoneal carcinomatosis.

Authors:  Y L B Klaver; V E P P Lemmens; S W Nienhuijs; G A P Nieuwenhuijzen; H J T Rutten; I H J T de Hingh
Journal:  Strahlenther Onkol       Date:  2013-01-19       Impact factor: 3.621

9.  Diffusion-weighted MRI in locally advanced rectal cancer : pathological response prediction after neo-adjuvant radiochemotherapy.

Authors:  M Intven; O Reerink; M E P Philippens
Journal:  Strahlenther Onkol       Date:  2012-12-19       Impact factor: 3.621

10.  Multiple malignancies in a single patient : a glimpse into 30 years of interdisciplinary oncology.

Authors:  B Berger; M Bamberg; D Zips; T Schlunk
Journal:  Strahlenther Onkol       Date:  2012-12-21       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.